Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur
New Delhi: Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur.
Representational image. Reuters
The US Food and Drug Administration (USFDA) issues an EIR to a company when an inspection is satisfactorily closed.
The health regulator had inspected the company's Nagpur manufacturing facility between 6 January and 10 January, 2020, Lupin Ltd said in a statement.
"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites," Lupin Managing Director Nilesh Gupta said.
also read
Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's and MSN Labs
The drug Baricitinib will be used in combination with Remdesivir for the treatment of patients requiring supplemental oxygen, invasive mechanical ventilation, Eli Lilly and Company said in a statement
OJEE 2021: Registration date extended till 15 June; check steps to apply here
The new dates of exams and downloading of admit cards will be decided after 15 June on assessment of the situation.
Crime of the Century: Alex Gibney on his upcoming documentary and the story of the opioid epidemic
The role of the Sackler family and their company, Purdue Pharma, in developing the prescription painkiller OxyContin is familiar territory. Gibney’s film digs into the aftermath, including the push to get doctors to overprescribe the medication and the company’s use of former government regulators to cripple serious oversight.